Innate-like T cell profile in myeloma: Severe deficiency of Vγ9Vδ2 T cells in aminobisphosphonate-treated patients.
a Haematology Laboratory , Capital and Coast District Health Board , Wellington , New Zealand .
Mairéad
M
Walsh
a Haematology Laboratory , Capital and Coast District Health Board , Wellington , New Zealand .
Glennis
G
White
b Wellington Blood and Cancer Centre, Capital and Coast District Health Board , Wellington , New Zealand .
Kenneth
K
Romeril
b Wellington Blood and Cancer Centre, Capital and Coast District Health Board , Wellington , New Zealand .
Huib
H
Buyck
b Wellington Blood and Cancer Centre, Capital and Coast District Health Board , Wellington , New Zealand .
Matthew
M
Stephens
c Malaghan Institute of Medical Research , Wellington , New Zealand .|d Centre for Public Health Research, Massey University , Wellington , New Zealand , and.
Collin
C
Brooks
b Wellington Blood and Cancer Centre, Capital and Coast District Health Board , Wellington , New Zealand .|c Malaghan Institute of Medical Research , Wellington , New Zealand .|e Department of Pathology and Molecular Medicine , University of Otago Wellington , Wellington , New Zealand.
Robert
R
Weinkove
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007113:Immunity, Innate; D018655:Lymphocyte Count; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism*; D010641:Phenotype; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D016692:Receptors, Antigen, T-Cell, gamma-delta